Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hunan Province Tumor Hospital
This phase 1c study will include patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, primary endpoint of this study is 6 week disease control rate(DCR, CR+PR+SD), secondary endpoints include progression free survival(PFS), overall survival(OS), quality of life(QOL) and drug safety.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
advanced non-small cell lung cancer, stage IIIB/IV who had received more than 2 standard treatment scheme
18-75 years old, anticipate overall survival more than 3 months, ECOG 0-2
within 4 weeks, not receive chemotherapy, radiotherapy or surgery
HB≥90g/L; ANC ≥1.5×109/L;PLT ≥80×109/L
EGFR/ALK mutation negative
immunohistochemistry test of cancer tissue showed ++ or +++ of thioredoxin reductase
brain metastasis without symptoms
You may not be if
according to NCCN non-small cell lung cancer guidelines (2014 v3), there were standard treatment scheme for the patients